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Abstract
Patients with venous thromboembolism (VTE) should receive a decision on the duration of anticoagulant treatment (AT) that is
often not easy to make. Sixteen Italian clinical centers included patients with recent VTE in the START2-POST-VTE register
and reported the decisions taken on duration of AT in each patient and the reasons for them. At the moment of this report,
472 (66.9%) of the 705 patients included in the registry were told to stop AT in 59.3% and to extend it in 40.7% of patients.
Anticoagulant treatment lasted 3 months in >90% of patients and was extended in patients with proximal deep vein thrombosis
because considered at high risk of recurrence or had thrombophilic abnormalities. D-dimer testing, assessment of residual
thrombus, and patient preference were also indicated among the criteria influencing the decision. In conclusion, Italian doctors
stuck to the minimum 3 months AT after VTE, while the secondary or unprovoked nature of the event was not seen as the
prevalent factor influencing AT duration which instead was the result of a complex and multifactorial evaluation of each patient.
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Introduction
Venous thromboembolism (VTE), which includes deep vein
thrombosis (DVT) and/or pulmonary embolism (PE), is a fre-
quent and severe disease whose incidence in developed coun-
tries is as high as 1 to 2 per 1000 persons per year. Venous
thromboembolism is an acute disease that may have variable
early and late outcomes after initial presentation. Patients with
acute VTE need immediate active anticoagulant treatment
(AT) that is currently performed using different drugs. Guide-
lines unanimously recommend at least 3 to 6 months to ade-
quately treat the acute episode.1-4 An extended treatment may
be indicated in some patients to prevent delayed recurrence.
Although anticoagulation is highly effective against recur-
rence, its benefit unfortunately is lost after discontinuation,
regardless of duration.5,6 Recurrence rate after a first VTE is
generally high, with a cumulative incidence after interrupted
anticoagulation that may reach 18%, 25%, and even 30% after
2, 5, and 8 years, respectively.7
The risk of VTE recurrence is not the same in all patients
after a first VTE. Extended anticoagulation beyond the first 3 to
6 months of therapy should be considered in some patients,
such as those with unprovoked events or with a persistent risk
factor for VTE, because of their high risk of recurrence though
not in all patients. Conversely, it is not indicated in patients
who may have low risk of recurrence or high risk of bleeding
when receiving anticoagulant therapies, thus avoiding the asso-
ciated risk of bleeding.2 The decision on whether to stop antic-
oagulation after the first 3 to 6 months from the acute event or
to extend it indefinitely (with periodical reassessment of patient
condition) will depend on carefully assessing the risk of recur-
rence against that of bleeding. However, estimating the risks of
recurrent VTE if AT is discontinued and that of bleeding com-
plications if AT is extended is not an easy task for any treating
physician. Recent reports, with data coming from different
countries, confirm a wide variability in the practice of physi-
cians as regards AT duration in management of patients with
VTE.8,9 Although it is relevant to assess to what extent physi-
cians follow the guidelines on this issue, it is also very impor-
tant to understand how the treating physicians tackle the issue
in daily clinical practice; many factors may influence their
decision, such as personal experience, confidence in guideline
recommendations, and patient characteristics and preferences.
The aim of the START2 POST-VTE register study is to
investigate how Italian physicians deal with this issue; in par-
ticular, when they take a decision on duration of AT after a
recent VTE episode, which decision is taken and why, and what
happens during follow-up of the patients. The present analysis
examined only the patients who had already received a decision
on AT at the moment of analysis.
Materials and Methods
The START2 Register (Survey on anticoagulated pAtients
RegisTer; NCT02219984) is a multicenter, prospective,
observational ongoing registry which is described in detail
elsewhere.10
The START2 POST-VTE is a branch of the START2-
Register that includes patients with recent VTE episode who
have given their written informed consent. Nine thrombosis
centers affiliated to the Italian Federation of Anticoagulation
Clinics participated in the START2 POST-VTE register,
together with 4 centers operating in Angiology departments,
2 centers in departments of Internal Medicine and 1 vascular
professional doctor (listed in Appendix A). All the attending
physicians were expert vascular doctors.
The patient information was electronically collected in
strictly anonymous form in the central database of the registry.
The inclusion of patients started in April 2017. At inclusion of
each patient physicians participating in the registry were asked
to collect: demographic and clinical characteristics, associated
risk factors for bleeding and thrombotic complications, routine
laboratory data, type, site and clinical aspects of the index VTE
episode and time of its occurrence, type of anticoagulant ther-
apy used, and presence of concomitant drugs. Laboratory tests,
all optional, were performed by local hospital laboratories.
When to take the decision on AT duration was left to the dis-
cretion of the attending physicians, who had to declare (a)
when they evaluated the patient after index event to decide
on duration of AT, (b) what their decision was, and (c) the
reasons for the decision. Participating doctors were also asked
to follow-up the patients for at least 6 months after the decision
was taken.
To evaluate whether and to what extent the presence of
comorbid conditions may have influenced the physician’s deci-
sion to extend anticoagulation or to stop any treatment, we
calculated the Charlson’s weighted comorbidity index score,
that combines both age and comorbidity.11 We decided to stra-
tify the weighted comorbidity index into 3 classes: mild, for
patients with scores 0 to 1; moderate, for patients with scores 2
to 4; and severe, for patients with scores 5.
Statistical Analysis
Descriptive analysis was performed. Continuous variables are
expressed as median with interquartile range (IQR) or as mean
plus or minus standard deviation (SD). Categorical variables
are expressed as frequencies and percentages. Preliminary sta-
tistical analysis was performed using Wilcoxon signed-rank
test (continuous variables) or Fisher exact test (categorical
data). A P value <.05 was considered statistically significant.
Univariate logistic regression analysis was performed to
explore the association between the clinical condition and the
decision of extending AT. All variables were subsequently
entered into a multivariable analysis, and a multiple logistic
regression with backward selection was performed to identify
the most relevant factors associated with the decision of longer
courses of anticoagulation. The results were given as OR with
their 95% CI. A P < .05 was considered statistically significant.
The SPSS software for Windows, version 25 (SPSS Inc) is used
for data processing.
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Results
Participant Centers and Baseline Patient Characteristics
At the time of the present analysis (June 30, 2019), 705 patients
with VTE were included in the registry. At that moment, 472
(66.9%) of them had already received a decision on duration of
AT, whereas the remaining 233 patients had not (206 of them
were on AT <180 days, and 27 for >180). The present analysis
examined only the 472 patients who had received a decision on
AT. Their baseline characteristics are shown in Table 1. The
median age was 68 years. In about two-thirds of patients, the
index VTE episode was proximal DVT, with or without PE,
whereas in 20% it was isolated distal DVT and in 10.8% of cases
isolated PE. The events were considered secondary or idiopathic
almost in the same proportion (52% and 48%, respectively). The
large majority of patients (83%) received a direct oral anticoa-
gulant (DOAC) as anticoagulant drug—in many cases rivarox-
aban, the first of these drugs available for this indication in our
country—while very few received VKAs (6%). A few patients
(7.7%) also received low-dose acetylsalicylic acid (ASA). The
presence of at least one comorbidity or risk factor was frequent
in the patients (43.9%). At inclusion, the physicians were also
asked to give an evaluation on the risk of bleeding and recurrent
VTE for each patient. These risks were estimated and reported in
only 60% of the patients and were judged to be low/interme-
diated in the majority of cases (83.4% and 67.8%, for bleeding
and recurrent events, respectively); however, in a non-negligible
portion of patients, the physicians declared they were unable to
evaluate these individual risks (4.5% and 7.1%, respectively).
Results of Patient Examination and Decision on Duration
of Anticoagulant Treatment
Table 2 shows the characteristics of the patients recommended to
discontinue or extend AT. The time interval from starting AT
and the moment of examination was 181 + 164 days (mean +
SD). In 59.3% of patients, the decision was to stop anticoagula-
tion. The duration of AT already performed at the time of exam-
ination was shorter in these patients than in those in whom the
decision was to extend anticoagulation, thus suggesting that in
many cases the treating physician had already made up his mind
from early treatment. Almost half of patients who discontinued
anticoagulation had an index event that was considered idio-
pathic, and a similar proportion of patients extended treatment
with an event that was associated with strong risk factors such as
prolonged bed resting, major surgery, and chronic inflammatory
disease. Anticoagulation was discontinued in a high proportion
of patients with isolated distal DVT. No significant differences
were found in the type of anticoagulant drug used and the con-
comitant antiplatelet treatment. At least one comorbidity or risk
factor was equally present in patients who extended or stopped
anticoagulation (9.8% and 9.1%, respectively). Many patients
with thrombophilic alterations were recommended to extend
anticoagulation. When the Charlson weighted comorbidity index
(that included both the presence of comorbidities and age-
classes) was calculated, more patients with a mild risk score
Table 1. Baseline Characteristics of Investigated Patients.
Patients n ¼ 472
Age at index event, median (IQR) years 68 (52-78)
<60 years, % 34.3
60-69 years, % 21.6
70-79 years, % 26.1
80 years, % 18.0
Men, % 54.0
Site of index event, %
DVT (proximal) 57.1
DVT þ PE 14.4
Isolated PE 10.8
Isolated distal DVT 17.7
Nature of index event
Idiopathic, n (%) 237 (50.2)
Secondary, n (%) 235 (49.8)
Bed resting (>3 days, within 3 months) 37.7
Immobilization (within 3 months) 13.2
Major surgery (within 3 months) 17.6
Cancer 12.1
Combined hormonal therapy 7.8












Presence of comorbidities or risk factors, %
None 58.3
Previous TIA/stroke episode 3.8
Previous major bleeding episode 3.8
Hypertension (drug treatment) 39.1
Diabetes 9.5
Ischemic heart/peripheral diseases 3.4/1.9
Heart failure 1.7
Chronic inflammatory diseases 4.7
Active cancer 7.6 8
Renal function (mL/min, median [IQR]) 4 (62; 105)
Severe renal insufficiency (<30 mL/min) 1.6











Abbreviations: DOAC, direct oral anticoagulant; DVT, deep venous thrombo-
sis; IQR, interquartile range; LMWH, low-molecular-weight heparin; PE, pul-
monary embolism; TIA, transient ischemic attack; VKA, vitamin K antagonist;
VTE, venous thromboembolism.
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(0-1 factor) discontinued anticoagulation (P ¼ .0001), whereas
more patients with moderate score (2-4 factors) extended ther-
apy. As expected, high bleeding or recurrence risks were closely
associated with discontinuation or extension of AT, respectively.
At the moment of examination or shortly before, only a few
patients were recommended to perform tests, including D-dimer
testing, compression ultrasonography of deep leg veins (46.5%
of patients with DVT), echocardiography, and/or pulmonary
perfusion scintigraphy (26% and 4% of patients with PE,
respectively).
To identify the most relevant factors associated with the
decision of longer courses of anticoagulation, a univariate anal-
ysis was performed. Subsequently, a multivariate analysis with
backward selection showed that thrombophilia abnormalities,
proximal DVT as index event and evaluation of high recur-
rence risk were independently associated with the decision of
extending AT, whereas isolated distal DVT as index event was
a factor associated with a decision to discontinue AT (Table 3).
What Physicians Declared About the Reason/s for the
Decision
Table 4 shows the reasons put forward by physicians to support
their decision on discontinuation (Table 4A) or extension
(Table 4B) of anticoagulation treatment. In most cases (almost
82% of patients), the decision to stop anticoagulation was laid
out at the beginning of AT. In almost one-third of patients, the
risk of recurrence was considered so low as to discourage treat-
ment extension. Physician or patient preference to stop AT was
also taken into account (altogether about 28% of cases). Less
frequently, the risk of bleeding complications was reported as a
reason for withdrawing AT. In less than one-fourth of patients,
a different antithrombotic treatment was suggested after the
standard AT was stopped (including sulodexide or ASA).
Table 2. Patients Examined by Treating Physicians and Recom-







Age, median (IQR) years 67 (51-78) 69 (57-78)
Duration of treatment at the
moment patients were
examined (months, mean+ SD)
8 + 7.1 11.2 + 10.4 .0001
<3 months (%) 8.7 9.2
3-6 months 54.5 34.4 .0003
7-12 months 29.3 28.1
>12 months 7.5 28.2 .0001
Site of index event, %
Proximal DVT 53.4 60.8
DVT þ PE 11.1 17.6
Isolated PE 8.4 13.2 .03
Distal DVT 27.1 8.3 .001
Nature of index event:
Unprovoked, n (%) 129 (46.1) 108 (56.3) .03
Provoked 151 (53.9) 84 (43.7)






Major surgery (within 3
months)
18.0 16.6
Combined hormonal therapy 13.0 3.2 .02
Laparoscopic surgery 0.4 2.4
Long travel - 1.0
Persisting major factors
Cancer 6.0 18.6 .003
Chronic inflammatory diseases 4.4 9.8
Other - 5.6
















































Thrombophilia abnormalities 13.0 22.5 .008
High risk of bleeding, % 7.5 0.5 .002
High risk of recurrent VTE, % 8.6 42.1 .0001
Charlson’s weighted comorbidity
index, score
0-1 (mild) 97 (34.6) 47 (24.5) .0001
2-4 (moderate) 100 (35.7) 87 (45.3) .004
5 (severe) 83 (29.6) 58 (30.2)
Abbreviations: AC, anticoagulation treatment; DOAC, direct oral anticoagu-
lant; DVT, deep venous thrombosis; LMWH, low-molecular weight heparin;
PE, pulmonary embolism; TIA, transient ischemic attack; VKA, vitamin K
antagonist; VTE, venous thromboembolism.
a Only significant results are shown.
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Table 4 reasons given by treating physicians to support dis-
continuation (A) or extension (B) of anticoagulation treatment
(more than one reason may have been attributed to the same
patient).
The most frequent condition leading to AT extension (Panel
B) was the unprovoked nature of the index event, followed by
the presence of residual vein thrombosis and the fact that the
event was a recurrent VTE. In general, AT was extended by
using the same drug as before; however, in 26 patients receiving
apixaban (about one-third of those who were treated with this
DOAC), the dose was reduced from 5 to 2.5 mg, twice daily.
The attending physicians were also asked to choose among
prespecified general criteria they often used to inform their
decision. Only one participant said he followed the recommen-
dations of the ACCP guidelines.2 The majority of participants
(45%) chose the global term “Management” as a general cri-
terion adopted, which included personal and clinical character-
istics of the patient, results of objective tests (especially
Compression UltraSonography), laboratory tests (especially
D-dimer and thrombophilia assays), and assessment of individ-
ual bleeding and thrombotic risks. Many participants (30%)
said they used D-dimer assay after anticoagulation was tempo-
rarily stopped to decide whether to definitively stop or resume
anticoagulation. Very few participants (4%) used one of the
available predictive scores (DASH, Vienna or Khorana scores).
A significant proportion of participants (about 20%) refused to
declare the prevalent criterion for their decision.
Discussion
Starting on April 2017, the START POST-VTE registry
included patients with a recent VTE episode, focusing in par-
ticular on the decisions taken by their treating physicians
regarding anticoagulation duration, and the reasons guiding
those decisions. More than 80% of the included patients were
treated with a DOAC, whereas only 6% received a VKA, thus
proving that most Italian doctors currently prefer DOACs over
VKAs for acute and long-term treatment of patients with VTE.
International guidelines recommend that patients with acute
Table 4. Reasons Given by Treating Physicians to Support Disconti-
nuation (A) or Extension (B) of Anticoagulation Treatment (More
Than One Reason May Have Been Attributed to the Same Patient).
A. Discontinuation
Total patients, n (%) 280
Males 137 (49.2)
Age years, median (IQR) 67 (51-78)
End of the planned treatment period 229 (81.8)
Low risk of recurrence 81 (28.9)
Treating physician’s preference 49 (17.5)
Negative d-dimer procedure 45 (16.1)
Patient preference 30 (10.7)
High bleeding risk 21 (7.5)
Tendency to fall 11 (3.9)
Presence of contraindications to extended treatment 10 (3.6)
Use of a predictive score 9 (3.2)
Major bleeding event (previous or during
anticoagulation)
4 (1.4)
Patient moved to another place 3 (1.2
Lost to follow-up 1 (0.4)
Patients addressed to a different drug treatment, n (%) 64 (22.8)
ASA 100 mg 14
Sulodexide 50
B. Extension
Total patients, n (%) 198
Males 117 (60.9)
Age years, median (IQR) 69 (57-78)
Unprovoked index event was 65 (33.8)
Presence of residual vein thrombosis 40 (20.8)
Recurrent VTE 37 (19.3)
Low bleeding risk 36 (18.7)
Positive D-dimer 34 (17.7)
Use of a predictive score 17 (8.8)
Post-thrombotic syndrome 16 (8.3)
Thrombophilia abnormalities 16 (8.3)
The index event was very serious 15 (7.8)
Patient preference 13 (6.8)
Positive family history for VTE 11 (5.7)
Other clinical indications for anticoagulation 11 (5.7)
Treating physician’s preference 7 (3.6)
Active cancer 5 (2.6)
Vena cava filter 1 (0.5)
Pulmonary hypertension 1 (0.5)
Treatment prescribed for extended anticoagulation
VKA 6
LMWH/Fondaparinux 13
Apixaban 5 mg BID 67
Apixaban 2.5 mg BID 26
Dabigatran 150 mg BID 3
Edoxaban 60 mg OID 25
Rivaroxaban 20 mg OID 58
Abbreviations: IQR, interquartile range; VTE, venous thromboembolism.
Table 3. Factors Associated With Longer Courses of Anticoagula-
tion: Univariate and Multivariate Logistic Analysis.
Factors
Univariate Multivariate
OR 95% CI P OR 95% CI P
Agea 1.7 0.90–2.0 .07 2.1 0.80–5.8 .1
Thrombophilia
abnormalities
2.5 1.4–5.1 .002 2.5 1.3–4.7 .003
Unprovoked event 1.8 1.1–6.2 .01 1.5 0.61–4.6 .3
Proximal DVT 2.1 1.3–4.1 .03 1.8 1.1–3.2 .04
Distal DVT 0.7 0.58–0.79 .01 0.2 0.72–0.82 .02
Isolated PE 2.8 1.5–5.4 .02 2.6 0.85–7.8 .06
Charlson’s score
(moderate)b
1.7 1.2–6.3 .05 1.7 0.58–4.9 .3
High risk of VTE
recurrencec
2.8 1.3–5.1 .01 2.2 1.1–4.6 .04
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; VTE,
venous thromboembolism.
aAge is considered as continuous variable.
bCharlson’s score moderate class versus mild/high classes.
cIndividual thrombotic risk assessment of patients formulated by the treating
physicians.
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VTE should receive AT for no less than 3 months.2 The results
in our cohort are in line with this recommendation, since very
few patients (7.2%), mainly those presenting with isolated dis-
tal DVT, stopped anticoagulation within 3 months of treatment.
The achieved adherence to not less than 3 months duration of
AT as recommended by guidelines should be underlined, since
a high prevalence of patients receiving AT for less than 3
months (involving more than 20% of the investigated patients)
is reported in the literature.12,13
The decision on AT duration was taken at a median time of
181 + 164 days from inclusion in the registry and was to stop
AT in 59.3% of patients. This timing for the decision may look
somewhat late since it might rather have been expected 3
months after AT. However, we are convinced that it represents
the practice of most Italian physicians who deem 6 months AT
as minimum duration after a VTE event. Furthermore, it does
not go against international guidelines, since they unanimously
recommend “no less” than 3 months2,4 or more explicitly, 3 to 6
months for long-term treatment.3 It is interesting to note, how-
ever, that 40% of patients who discontinued anticoagulation did
so after 6 months of the index event and at least 2 factors, in our
view, may have contributed to this: first, as mentioned before,
many Italian doctors are convinced that patients with VTE need
to receive about 6 months of AT, though its prolongation, albeit
of little benefit, cannot do any harm; second, our national
health service does not explicitly recommend or support the
practice of reexamining all patients 3 to 6 months after a VTE
episode and so treatment may continue beyond that period.
The present study showed that 40.7% of patients were rec-
ommended to extend anticoagulation; more than 50% of them
were notified when AT had already lasted >6 months, thus
indicating that the physicians had already made up their minds
to extend AT and were not particularly waiting for feedback
after 3 to 6 months of therapy.
Current international guidelines suggest an extended AT in
patients with unprovoked events,2 or when the risk of recurrent
events is classified as intermediate or high,4 provided that the
risk of bleeding complications is not high. Conversely, an
important part of our patient cohort (43.7%), in whom AT was
extended, had an index VTE event that was provoked, whereas
treatment was discontinued in a similar proportion (46.1%) of
patients whose event was idiopathic. These findings show that
our participating doctors do not deem the provoked or unpro-
voked nature of the event as the only or even prevalent factor
for deciding on duration of anticoagulation. Recent important
scientific reports support this view. In the EINSTEIN CHOICE
study, assessing the efficacy and safety of rivaroxaban (at stan-
dard or reduced daily dose) or aspirin use for extended treat-
ment, more than half of all included patients had provoked
VTE events.14 A recent study analyzing the risk of recurrent
VTE according to baseline risk factor profiles concluded that
“Recurrence rates in patients with VTE provoked by minor
persistent or minor transient risk factors were not significantly
lower than that with unprovoked VTE. Therefore, such patients
may also benefit from extended anticoagulation therapy.”15
Recent results of data from a nationwide Danish cohort showed
that the long-term (10 years) cumulative risk of recurrent VTE
was not much lower after provoked (about 16%) versus unpro-
voked (about 20%) events.16 Finally, in a recent commentary,
distinguished colleagues recommended stopping
“dichotomizing” VTE events as provoked or unprovoked.17
Although—in our results—age was not a criterion for prefer-
ring 1 of the 2 treatment options, other patient and/or event
characteristics have influenced the decision on AT duration, as
shown by the multivariate regression analysis. As expected,
patients with distal DVT more frequently stopped AT. Conver-
sely, AT was preferentially extended when the index event was a
proximal DVT, when risk of recurrent events was judged to be
high, when thrombophilic alterations were present. In line with
what some clinical studies have suggested,18-20 one-third of all
investigators used D-dimer testing to assess the risk of recurrent
events and help inform decision on duration of anticoagulation.
However, the general impression is that the participant physi-
cians used the results of D-dimer testing not as single criterion for
the decision; they mainly evaluated the results in the context of
other patient and/or event characteristics. In contrast, clinical
prediction rules were seldom used by investigators to help in
their decision. The presence of residual vein thrombosis was a
condition reported in about 20% of patients referred for extended
AT; this was in line with many scientific data pointing to a
relationship between the persistence of a residual thrombus and
an increased risk of thrombosis recurrence.21-23
On the basis of positive results of clinical trials,24,25 the
attending physicians suggested to about one-fourth of the
patients who discontinued AT to assume sulodexide or aspirin
as a substitute treatment in the months that followed. In some
patients, the therapy for extended treatment was shifted from
full- to low-dose apixaban; this was supported by results obtained
in the Amplify-Extension trial26 in which low-dose apixaban (2.5
mg twice daily) proved equally effective as and safer than stan-
dard dose (5 mg twice daily) for extended treatment, while in all
the remaining cases the original AT was maintained also for
extended therapy. It should be noted, however, that the EIN-
STEIN CHOICE trial14 showing a similar advantageous use of
low-dose rivaroxaban for extended treatment had only just been
published at the time of the present cohort study and so its results
had not yet been introduced into clinical practice.
Deriving from the everyday clinical practice of Italian vas-
cular doctors, our results show that the decision on duration of
AT in patients with VTE is an uneasy and complex task for
them. The final decision may be influenced by a wide variety of
factors and determinants that make it much more complicated
than sticking to the simple dualism between provoked or unpro-
voked events. In that sense, it can be said that the participating
treating physicians only partially follow the guideline indica-
tions. Two recent, survey-based studies, performed in different
geographic context (Australia and Northern Europe), have
investigated the physician’s attitude to adhere to the guideline
indications.8,9 Although in both studies most physicians said
they followed the guideline indications on the issue (very
likely, even our Italian physicians would have given the same
answer if asked), both studies showed a considerable variability
6 Clinical and Applied Thrombosis/Hemostasis
in VTE management practices, in a way similar to what we
found in our study. In particular, the difficulty in assessing the
individual patient risk of developing a major bleeding compli-
cation during AT was underlined in the study by de Winter
et al9 as well as in the present study.
In conclusion, when dealing with patients after a VTE epi-
sode, the Italian vascular doctors involved in the present study
generally stuck to the minimum 3-month period of AT recom-
mended by international guidelines. The treating physicians
made a decision to stop or extend AT that was not greatly
affected by whether the index event was secondary or unpro-
voked. This result may be attributed to their evaluation of the
etiology of the event (secondary or unprovoked) as part of a
series of many other factors, including the individual clinical
conditions of patients and presence of risk factors for either
bleeding or thrombosis. Although doctors in many patients
seemed to have already formed an opinion on the duration of
anticoagulation at the beginning of treatment, in many cases
the use of laboratory tests (ie, D-dimer) and/or CUS examina-
tions have guided their choice on duration of AT.
Appendix A
List of participating centers and investigators who contributed
to the START2 POST-VTE Registry
 Benilde Cosmi, Ludovica Migliaccio, UO di Angiologia
e Malattie Coagulazione, AOU S. Orsola-Malpighi,
Bologna, Bologna
 Antonella Caronna, Luca Sarti, Medicina Interna
d’Urgenza Nuovo Ospedale Civile S. Agostino Estense,
Modena
 Antonio Chistolini, Alessandra Serrao, Sezione Emato-
logia, Dipartimento di Biotecnologie Cellulari ed Ema-
tologia Azienda Ospedaliero Universitaria Policlinico
Umberto I, Roma
 Rosella Di Giulio, U.O. di Medicina Interna A, Ospedale
Maggiore, Bologna
 Anna Falanga, Teresa Lerede; Università Bicocca
Milano, Dept. Medicine and Surgery, Monza and USC
SIMT, Centro Emostasi e Trombosi, Ospedale Papa
Giovanni XXIII, Bergamo
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Sapienza Roma
 Daniela Poli, Lucia Martinese, Elisa Vignini, Eleonora
Camilleri, SOD Malattie Aterotrombotiche, Azienda
Ospedaliero Universitaria-Careggi, Firenze
 Manlio Prior, Sergio De Marchi, Anna Maria Rigoni
UOC di Angiologia, Azienda Ospedaliero Universitaria
Integrata Verona
 Luigi Ria, UO Medicina Interna, Presidio Ospedaliero di
Gallipoli (Lecce)
 Angelo Santoliquido Angela Di Giorgio UOS Angiolo-
gia Columbus, Policlinico Universitario Agostino
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